DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/33qqsz/facial_aesthetics) has announced the addition of GlobalData 's new report "Facial Aesthetics (Botulinum Toxin, Dermal Fillers) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018" to their offering.?
Botox Sales Increasing as Beauty Fans Seek No-Knife Alternative
Botox will continue its reign as a bestseller in US beauty clinics due to competitive pricing and reductions in side effects, according to a new report by medical intelligence company GlobalData.
The new report* states that facial aesthetics represent a popular cosmetic treatment, as they offer long-term results at competitive prices without any need for surgical procedures. Botox in particular is predicted to maintain its lead in terms of market share during future years, due to increased patient comfort, short procedure times and immediate results.
The dermal fillers market will grow in the future due to the increasing consumer preference for hyaluronic acid-based dermal fillers (HA fillers), which offer fewer side effects in exchange for results lasting just three to six months. This may be good news for aesthetic centers, as HA fillers will provide recurring income.
In contrast, the Particle and Polymer Fillers (PPF) market is expected to struggle, as the longevity of aesthetic results lasting up to two years is countered by a higher side effects profile. Collagen products will continue to experience their historic decline in sales, due to increasing awareness of other options such as botox and HA fillers.
Currently, no facial aesthetic procedure can offer permanency, and the longevity of results correlates with higher medical risks. Long-term market growth may depend upon the ability to extend the longevity of results from facial injections, in order compete more strongly against cosmetic surgery.? The entire global market for facial aesthetics is forecast to reach $4.7 billion in 2018, of which the US is expected to contribute over US$2 billion.
Companies Mentioned
Allergan, Inc
Q-Med AB (Subsidiary of Galderma S.A.)
Mentor Worldwide LLC (Subsidiary of Ethicon, Inc.)
Medicis Pharmaceuticals Corporation
Merz GmbH & Co. KGaA
For more information visit http://www.researchandmarkets.com/research/33qqsz/facial_aesthetics
Source: GlobalData